Literature DB >> 15539641

Adenosine A2A receptor and dopamine D3 receptor interactions: evidence of functional A2A/D3 heteromeric complexes.

Maria Torvinen1, Daniel Marcellino, Meritxell Canals, Luigi F Agnati, Carmen Lluis, Rafael Franco, Kjell Fuxe.   

Abstract

Adenosine A(2A) and dopamine D(2) receptors have been shown previously to form heteromeric complexes and interact at the level of agonist binding, G protein coupling, and trafficking. Because dopamine D(2) and D(3) receptors show a high degree of sequence homology, A(2A) and D(3) receptors may also interact in a similar manner. The present studies with confocal microscopy showed that A(2A)-yellow fluorescent protein (YFP) and D(3)-green fluorescent protein 2 (GFP2) receptors colocalize in the plasma membrane. Furthermore, fluorescence resonance energy transfer (FRET) analysis demonstrated that A(2A)-YFP and D(3)-GFP2 receptors give a positive FRET efficiency and are thereby likely to exist as heteromeric A(2A)/D(3) receptor complexes. Saturation experiments with [(3)H]dopamine demonstrated that the A(2A) receptor agonist 4-[2-[[6-amino-9(N-ethyl-beta-d-ribofuranuronaminoamidosyl)-9H-purin-2-yl]amino]ethyl]benzenepropanoic acid (CGS-21680) reduced the affinity of the high-affinity agonist binding state of the D(3) receptor for [(3)H]dopamine. The A(2A) and D(2A) receptors seem to interact also at the level of G protein coupling, because the adenosine A(2A) receptor agonist CGS-21680 fully counteracted the D(3) receptor-mediated inhibition of a forskolin-mediated increase in cAMP levels. Taken together, when coexpressed in the same neuron, A(2A) and D(3) receptors seem to form A(2A)/D(3) heteromeric receptor complexes in which A(2A) receptors antagonistically modulate both the affinity and the signaling of the D(3) receptors. D(3) receptor is one of the therapeutic targets for treatment of schizophrenia, and therefore, the A(2A)/D(3) receptor interactions could provide an alternative antischizophrenic treatment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15539641     DOI: 10.1124/mol.104.003376

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  41 in total

Review 1.  On the expanding terminology in the GPCR field: the meaning of receptor mosaics and receptor heteromers.

Authors:  Luigi F Agnati; Diego Guidolin; Jean Pierre Vilardaga; Francisco Ciruela; Kjell Fuxe
Journal:  J Recept Signal Transduct Res       Date:  2010-10       Impact factor: 2.092

Review 2.  Adenosine-dopamine interactions in the pathophysiology and treatment of CNS disorders.

Authors:  K Fuxe; D Marcellino; D O Borroto-Escuela; M Guescini; V Fernández-Dueñas; S Tanganelli; A Rivera; F Ciruela; L F Agnati
Journal:  CNS Neurosci Ther       Date:  2010-03-16       Impact factor: 5.243

Review 3.  Adenosine A2A and dopamine D2 heteromeric receptor complexes and their function.

Authors:  Kjell Fuxe; Sergi Ferré; Meritxell Canals; Maria Torvinen; Anton Terasmaa; Daniel Marcellino; Steven R Goldberg; William Staines; Kirsten X Jacobsen; Carmen Lluis; Amina S Woods; Luigi F Agnati; Rafael Franco
Journal:  J Mol Neurosci       Date:  2005       Impact factor: 3.444

4.  Neonatal handling, sweet food ingestion and ectonucleotidase activities in nucleus accumbens at different ages.

Authors:  P P Silveira; G Cognato; L M Crema; F Q Pederiva; C D Bonan; J J Sarkis; A B Lucion; C Dalmaz
Journal:  Neurochem Res       Date:  2006-05-23       Impact factor: 3.996

5.  D1-D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of Gq/11 in the striatum.

Authors:  Asim J Rashid; Christopher H So; Michael M C Kong; Teresa Furtak; Mufida El-Ghundi; Regina Cheng; Brian F O'Dowd; Susan R George
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-28       Impact factor: 11.205

6.  Low affinity binding of the classical D1 antagonist SCH23390 in rodent brain: potential interaction with A2A and D2-like receptors.

Authors:  Sarah K Leonard; Penelope Ferry-Leeper; Richard B Mailman
Journal:  Brain Res       Date:  2006-09-07       Impact factor: 3.252

Review 7.  Intramembrane receptor-receptor interactions: a novel principle in molecular medicine.

Authors:  K Fuxe; M Canals; M Torvinen; D Marcellino; A Terasmaa; S Genedani; G Leo; D Guidolin; Z Diaz-Cabiale; A Rivera; L Lundstrom; U Langel; J Narvaez; S Tanganelli; C Lluis; S Ferré; A Woods; R Franco; L F Agnati
Journal:  J Neural Transm (Vienna)       Date:  2006-10-27       Impact factor: 3.575

Review 8.  Heteromeric dopamine receptor signaling complexes: emerging neurobiology and disease relevance.

Authors:  Melissa L Perreault; Ahmed Hasbi; Brian F O'Dowd; Susan R George
Journal:  Neuropsychopharmacology       Date:  2013-06-18       Impact factor: 7.853

Review 9.  Moonlighting proteins and protein-protein interactions as neurotherapeutic targets in the G protein-coupled receptor field.

Authors:  Kjell Fuxe; Dasiel O Borroto-Escuela; Wilber Romero-Fernandez; Miklós Palkovits; Alexander O Tarakanov; Francisco Ciruela; Luigi F Agnati
Journal:  Neuropsychopharmacology       Date:  2013-09-06       Impact factor: 7.853

Review 10.  Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease.

Authors:  Marie Therese Armentero; Annalisa Pinna; Sergi Ferré; José Luis Lanciego; Christa E Müller; Rafael Franco
Journal:  Pharmacol Ther       Date:  2011-07-23       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.